High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment.
Sánchez-Magraner L, Miles J, Baker CL, Applebee CJ, Lee DJ, Elsheikh S, Lashin S, Withers K, Watts AG, Parry R, Edmead C, Lopez JI, Mehta R, Italiano A, Ward SG, Parker PJ, Larijani B.
Sánchez-Magraner L, et al. Among authors: lee dj.
Cancer Res. 2020 Oct 1;80(19):4244-4257. doi: 10.1158/0008-5472.CAN-20-1117. Epub 2020 Aug 27.
Cancer Res. 2020.
PMID: 32855204